P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE

• B. Dhakal,
• H. Einsele,
• R. Potluri,
• J. Schecter,
• W. Deraedt,
• N. Lendvai,
• A. Slaughter,
• C. Lonardi,
• S. Nair,
• J. He,
• N. Joseph,
• P. Cost,
• S. Valluri,
• F. Yalniz,
• L. Pacaud,
• K. Yong

Affiliations

B. Dhakal

1 Medical College of Wisconsin, Milwaukee, United States of America

H. Einsele

2 Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Wuerzburg, Germany

R. Potluri

3 SmartAnalyst Inc, New York

J. Schecter

4 Janssen R&D, Raritan, United States of America

W. Deraedt

5 Janssen Pharmaceutica NV, Beerse, Belgium

N. Lendvai

4 Janssen R&D, Raritan, United States of America

A. Slaughter

6 Cilag GmbH International, Zug, Switzerland

C. Lonardi

7 Janssen, Buenos Aires, Argentina

S. Nair

5 Janssen Pharmaceutica NV, Beerse, Belgium

J. He

8 Janssen Global Services, LLC, Raritan

N. Joseph

9 Janssen Scientific Affairs, LLC, Horsham

P. Cost

8 Janssen Global Services, LLC, Raritan

S. Valluri

8 Janssen Global Services, LLC, Raritan

F. Yalniz

10 Legend Biotech USA, Piscataway, United States of America

L. Pacaud

10 Legend Biotech USA, Piscataway, United States of America

K. Yong

11 University College London Cancer Institute, London, United Kingdom